Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Genetic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SMC1A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SMC1A Recombinant Protein (ATPase Domain / Full Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for PPI and binding assays. |
View SMC1A Products |
| Gene Delivery | SMC1A Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and rescue assays. |
View SMC1A Products |
| Benchmark Ab | Anti-SMC1A Recombinant Antibody Sequence-verified recombinant positive control for Western Blot, IP, and IHC. |
View SMC1A Products |
| Validator | SMC1A siRNA Set Target-specific knockdown verification in functional genomic assays. |
View SMC1A Products |
| Related Target A | SMC3 Obligate heterodimer partner of SMC1A; essential for reconstituting functional cohesin ATPase activity. |
View SMC3 Products |
| Related Target B | RAD21 Kleisin subunit that bridges SMC1A and SMC3; key target for cohesin-disrupting small molecules. |
View RAD21 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting Cohesin Complex In Vitro | SMC1A and SMC3 co-expressed or highly purified individual subunits available with verified sequence identity. |
| ATPase Domain Off-Target Screening | Highly purified N- and C-terminal head domain fragments strictly verified by mass spectrometry to eliminate bacterial ATPase contamination. |
| Lack of Controls | Clinical-grade benchmark antibodies and validated siRNA sequences included for robust assay baselines. |
| False Positives | Multi-vial siRNA sets included to confirm phenotype specificity and rule out off-target gene silencing. |
Live SMC1A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SMC1A therapeutics is intensifying, with major players shifting focus from traditional genetic disease models to targeted oncology. As a core component of the cohesin complex, SMC1A represents a critical vulnerability in cancers harboring synthetic lethal mutations (such as STAG2-deficient tumors) and those exhibiting high replication stress. The next wave of R&D is targeting the disruption of the SMC1A-SMC3-RAD21 interface and utilizing PROTACs for targeted protein degradation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Oncology-focused Biotechs, Academic Institutions | Colorectal Cancer, Glioblastoma, STAG2-mutant Tumors | ATPase Activity & DNA Binding Assays (Need high-purity, active SMC1A/SMC3 heterodimers) |
| PROTAC / Degraders | Targeted Protein Degradation (TPD) Pioneers | Hematological Malignancies, Solid Tumors | Ternary Complex Formation Assays (Need sequence-verified, full-length SMC1A) |
| Gene Therapy / RNAi | Orphan Drug Developers | Cornelia de Lange Syndrome (CdLS), Cohesinopathies | Rescue & Knockdown Validation (Need high-titer Lentivirus and validated siRNA) |